Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
AIM ImmunoTech ( (AIM) ) has shared an update.
On November 18, 2025, AIM ImmunoTech Inc. entered into a Note Purchase Agreement with Streeterville Capital, LLC, resulting in the sale of an unsecured Promissory Note with a principal amount of $3,301,250. The transaction, which closed on the same date, involved a purchase price of $2,500,000 after accounting for an issuance discount and transaction costs. The Note bears a 10% annual interest rate, with a maturity date set for 24 months from issuance. The agreement includes mandatory prepayment terms tied to future fundraising activities and outlines conditions for default, which could lead to increased interest rates.
The most recent analyst rating on (AIM) stock is a Sell with a $1.50 price target. To see the full list of analyst forecasts on AIM ImmunoTech stock, see the AIM Stock Forecast page.
Spark’s Take on AIM Stock
According to Spark, TipRanks’ AI Analyst, AIM is a Underperform.
AIM ImmunoTech’s overall stock score is primarily impacted by its poor financial performance and bearish technical indicators. The company’s financial instability, characterized by negative equity and cash flow issues, is the most significant factor. The technical analysis further supports a negative outlook with indicators pointing to an oversold and downtrending stock. Valuation concerns, including a negative P/E ratio, also contribute to the low score.
To see Spark’s full report on AIM stock, click here.
More about AIM ImmunoTech
Average Trading Volume: 100,576
Technical Sentiment Signal: Sell
Current Market Cap: $3.98M
See more insights into AIM stock on TipRanks’ Stock Analysis page.